Patents Examined by Robert C. Hayes
  • Patent number: 10808034
    Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PrPC. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: October 20, 2020
    Assignee: MedImmune Limited
    Inventors: Matthew Gardener, Jayne Hammersley, Maria Groves, Gareth Rees, Sadhana Podichetty, Andrew Billinton
  • Patent number: 10800836
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: October 13, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Patent number: 10800830
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 13, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • Patent number: 10772928
    Abstract: Methods for treatment and diagnosis of neurological disorders such as autism and autism spectrum disorder are disclosed. Also disclosed are modulators of alternative splicing regulators SRRM4 and/or SRRM3 for treating neurological disorders. Further disclosed are agents that modulate the expression of at least one splice variant for treating neurological disorders. Mouse models of neurological disorders having increased or decreased expression of SRRM4 and/or SRRM3 are also disclosed.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: September 15, 2020
    Assignees: The Governing Council of the University of Toronto, Sinai Health System
    Inventors: Benjamin J. Blencowe, Mathieu Quesnel-Vallieres, Manuel Irimia, Bushra Raj, Sabine P. Cordes
  • Patent number: 10751387
    Abstract: The instant disclosure relates to methods and compositions for the treatment of Gaucher disease, particularly type II and III neuronopathic Gaucher disease (nGD). The methods include the step of administering to an individual in need thereof an effective amount of a ryanodine receptor inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: August 25, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Ying Sun, Benjamin Liou
  • Patent number: 10752675
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: August 25, 2020
    Assignee: GENEURO S.A.
    Inventors: Herve Perron, Reza Firouzi, Patrick Küry, Raphaël Faucard, Alexandra Madeira, Julie Joanou
  • Patent number: 10745471
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: August 18, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
  • Patent number: 10736961
    Abstract: A method of averting opioid addiction in a patient is disclosed. The method can be applied to a patient suffering from moderate to severe low back pain (LBP). The method comprises: diagnosing the patient as suffering from low back; administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and avoiding administration of an opioid to the patient, and thereby relieving pain, and averting opioid addiction in a patient.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: August 11, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Catherine Stehman-Breen, John Davis
  • Patent number: 10729749
    Abstract: The invention relates to novel peptides, compositions, therapies and methods for treating neurodegenerative disorders, for example Alzheimer's disease.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: August 4, 2020
    Assignee: NEURO-BIO LTD.
    Inventors: Susan Adele Greenfield, Gwenael Pottiez, Sara Esther Garcia-Rates
  • Patent number: 10702555
    Abstract: The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: July 7, 2020
    Assignee: NEURALSTEM, INC.
    Inventors: Thomas Hazel, Karl K. Johe
  • Patent number: 10689426
    Abstract: Disclosed is a polypeptide containing an extracellular domain of a synaptogenic protein, and a method for manufacturing a nerve cell, a complex containing a biotin tagged at the C-terminus of the polypeptide, an artificial synapse inducer for coupling the composite to a streptavidin (SAV)-coated substrate and a nerve cell. The complex tagged with a biotin at the C-terminus of the polypeptide containing the extracellular domain of the synaptogenic protein, such as neuroligin-1, can display activity by being attached to the SAV-coated substrate to adjust the orientation thereof without help of a supported lipid bilayer. The complex containing an additional RFP between the extracellular domain and the biotin of the synaptogenic protein not only facilitates easier mass-production, quantification, and tracking, but also displays activity of a normal synaptogenic protein, thereby inducing excitatory or inhibitory synaptic differentiation by being fixed to the substrate and added to the nerve cell culture.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: June 23, 2020
    Assignee: Seoul National University R&DB Foundation
    Inventors: Taek Dong Chung, In Seong Hwang, Eun Joong Kim, Chang Su Jeon
  • Patent number: 10682373
    Abstract: The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor or expression inhibitor as an active ingredient.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 16, 2020
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATION
    Inventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
  • Patent number: 10682393
    Abstract: The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: June 16, 2020
    Assignees: Emory University, The United States Department of Veterans Affairs
    Inventor: Shanthi Srinivasan
  • Patent number: 10668152
    Abstract: This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
    Type: Grant
    Filed: June 3, 2017
    Date of Patent: June 2, 2020
    Assignees: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.
    Inventors: Vladimir Coric, Tibor Keler, Thomas Davis
  • Patent number: 10647764
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 12, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Patent number: 10647763
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 12, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Patent number: 10640552
    Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e.g. neurons, astrocytes and microglial cells).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: May 5, 2020
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Christophe Prehaud, Monique Lafon, Pierre Lafaye
  • Patent number: 10640554
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 5, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Patent number: 10632169
    Abstract: Biomarkers are not as commonly used in ALS drug development as in the drug development process for oncology. Biomarkers are important component of the ALS drug development pathway to demonstrate drug effect and target engagement. In a recent Phase 2A double-blind, randomized, placebo controlled clinical trial with GM604 (AKA MNTF, GM6), where ALS patients were treated with six doses of GM604 for two weeks and then continued to be evaluated for disease progression until 10 weeks after cessation of GM604 treatment, it was demonstrated that GM604 can modulate expression of ALS disease related genes, through pathways that bring about homeostasis of pertinent ALS biomarkers. The statistical significance in biomarker changes also correlate with treatment effects in clinical observations.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 28, 2020
    Assignee: Genervon Biopharmaceuticals, LLC
    Inventors: Pui-Yuk Dorothy Ko, William R. Swindell
  • Patent number: 10624925
    Abstract: This document provides methods and materials for producing CD8+ T cells. For example, methods and materials for using low glucose levels (e.g., from about 0.3 mM to about 0.7 mM glucose) to culture cells to produce particular populations of T cells (e.g., CD8+ T cells such as tissue resident memory T cells) are provided.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 21, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Protul Shrikant